Phaseline

Companies › Suzhou BlueHorse Therapeutics

Suzhou BlueHorse Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LM103 TILs Injection
Autologous tumor-infiltrating lymphocytes (TILs) extracted, cultured and expanded from pat
–Phase 2Advanced Melanoma; Non-Small Cell Lung Cancer; MelanomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07310784LM103 TILs InjectionPhase 2Advanced MelanomaOncologyDec 2027
NCT07444437LM103 TILs InjectionPhase 2Non-Small Cell Lung CancerOncologyDec 2027
NCT05366478LM103 TILs InjectionPhase 1MelanomaOncologyMay 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vasgene Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics Tessa Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.